Famciclovir is a guanine analog antiviral drug used commonly for herpes zoster. Efficacy of famciclovir treatment has been reported to be comparable to valacyclovir treatment. Both of these medications reduce the time to complete cessation of zoster-associated pain including post-herpetic neuralgia, as compared to acyclovir. We conducted a multicenter, randomized, open clinical trial in order to evaluate the extent of pain relief afforded by these two antiviral drugs during the acute disease phase of herpes zoster. The study group comprised 86 immunocompetent adult patients suffering from herpes zoster, who were treated with either famciclovir or valacyclovir for 7 days. Of these, 55 patients enrolled in this study within 72 h of the onset of the rash and 31 patients after 72 h of the onset. There was a significant reduction in acute herpes zoster pain with famciclovir on day 7 and at 2-3 weeks in both of these patient groups, while with valacyclovir, there was not significant reduction in pain on day 7. Of patients aged 50 years or older, there was a significantly earlier reduction in pain with famciclovir than with valacyclovir. In addition, a significant reduction in the number of patients with pain was observed as early as days 3-4 with famciclovir treatment as compared with valacyclovir treatment. We conclude that famciclovir was superior to valacyclovir in the relief of acute pain of herpes zoster. Accordingly, famciclovir is recommended for herpes zoster patients with moderate symptoms and a visual analog scale score of under 50 mm.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1346-8138.2012.01584.x | DOI Listing |
Med Sci Monit
December 2024
Department of Neurology, HangZhou Third People's Hospital, Hangzhou, Zhejiang, China.
BACKGROUND This study aimed to analyze the risk factors of central nervous system (CNS) infection caused by reactivation of varicella zoster virus (VZV) and provide reference for the prevention and early diagnosis of VZV-associated CNS infection. MATERIAL AND METHODS A prospective study was conducted on 1030 patients with acute herpes zoster (HZ) admitted to our hospital from January 2021 to June 2023. According to clinical manifestations and auxiliary examinations, they were divided into HZ group of 990 patients and VZV-associated CNS infection group of 40 patients.
View Article and Find Full Text PDFClin Pract
December 2024
Department of Gynecology and Obstetrics, University Hospital, Philipps-University Marburg, Baldingerstraße, 35043 Marburg, Germany.
Purpose: The purpose of this study was to investigate a possible association between Herpes Zoster (HZ) and the subsequent diagnosis of breast cancer (BC).
Methods: Utilizing the Disease Analyzer database, anonymized medical records from German office-based practices were accessed. Longitudinal data of female patients aged 18 years and above diagnosed with HZ between 2005 and 2021 were included.
Clin Microbiol Infect
December 2024
Department of Infectious Diseases, Aalborg University Hospital, 9000 Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, 9000 Aalborg, Denmark; European Society of Clinical Microbiology and Infectious Diseases Study Group of Infections of the Brain (ESGIB).
Background: Infectious encephalitis poses a global health challenge with a high mortality and severe neurological consequences in survivors. Emerging pathogens and outbreaks are reshaping the patterns of the disease.
Objective: To understand the current epidemiology for improving prevention, diagnosis, and treatment.
Cureus
November 2024
Department of Pain Medicine, Fondazione Paolo Procacci, Rome, ITA.
The present investigation evaluated transcutaneous electrical nerve stimulation (TENS) for the non-pharmacological treatment of post-herpetic neuralgia (PHN). PHN is the most common complication of the Herpes Zoster virus, affecting one in every five patients with shingles, and presents as intense neuropathic pain that can persist for 90 days or longer after the initial onset of symptoms. Current pharmacological treatment options are mainly limited to symptom management, including oral medications such as tricyclic antidepressants and gabapentinoid preparations, as well as topical options such as lidocaine or capsaicin.
View Article and Find Full Text PDFJ Family Med Prim Care
November 2024
Department of Oral Medicine and Radiology, CSI College of Dental Sciences and Research, Madurai, Tamil Nadu, India.
Herpes zoster is an acute viral infection caused by the reactivation of the varicella zoster virus. It occurs commonly in immunocompromised adults. Odontalgia may be an early prodromal symptom when herpes zoster involves the oral and maxillofacial region, which lays significant emphasis on the role of a dentist in early diagnosis and treatment of the infection.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!